Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$JANX

DatePrice TargetRatingAnalyst
12/3/2024$82.00 → $100.00Buy
BTIG Research
12/3/2024$63.00 → $70.00Buy
H.C. Wainwright
11/22/2024$79.00Outperform
Leerink Partners
10/24/2024$69.00Buy
UBS
9/6/2024$70.00Buy
Stifel
5/30/2024$47.00Sector Perform
Scotiabank
3/21/2024$62.00Buy
BTIG Research
3/20/2024$100.00Overweight
Cantor Fitzgerald
More analyst ratings

$JANX
Press Releases

Fastest customizable press release news feed in the world

See more
  • Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical Officer

    Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the promotion of Dr. Zachariah McIver to Chief Medical Officer. "The appointment of Zach to CMO is an important milestone for Janux. Zach's expertise in T cell engagers has brought significant value to our organization and he has been essential in our efforts to optimize the clinical development of our PSMA-TRACTr and clinical pipeline," said David Campbell, Ph.D., President and CEO of Janux.

    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Clear Street Launches Healthcare & Biotechnology Equity Research

    Comprehensive Biotechnology sector market analysis and investment insights complement recently launched Disruptive Technology and Energy Transition franchises Clear Street, ("Clear Street", "the Company") a cloud-native financial technology firm on a mission to modernize the brokerage ecosystem, today announced the expansion of its recently launched equity research offering with the addition of Healthcare, initially focused on the biotechnology sector. The expanded research offering complements Clear Street's leading prime brokerage and clearing solutions for its rapidly growing client base of asset managers, institutions and professional traders across equities, fixed income, derivatives

    $CGEM
    $CRGX
    $DCTH
    $ELVN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical/Dental Instruments
    Biotechnology: Pharmaceutical Preparations
  • Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million

    Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the closing of its previously announced underwritten public offering of 6,150,793 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase up to 833,333 additional shares of common stock, at a public offering price of $63.00 per share and pre-funded warrants to purchase 238,095 shares of common stock at a price of $62.999 per pre-funded war

    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$JANX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$JANX
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$JANX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$JANX
SEC Filings

See more

$JANX
Leadership Updates

Live Leadership Updates

See more
  • Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical Officer

    Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the promotion of Dr. Zachariah McIver to Chief Medical Officer. "The appointment of Zach to CMO is an important milestone for Janux. Zach's expertise in T cell engagers has brought significant value to our organization and he has been essential in our efforts to optimize the clinical development of our PSMA-TRACTr and clinical pipeline," said David Campbell, Ph.D., President and CEO of Janux.

    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Janux Therapeutics Announces Updates to Board of Directors

    The appointment of Eric Dobmeier and Natasha Hernday to the Board brings extensive operational and business development experience to support corporate and pipeline strategy Janux also announced the resignation of Jay Lichter, Ph.D., from the Board, and the appointment of current Board member Ronald W. Barrett, Ph.D., as Chairperson Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the appointment of Eric Dobmeier and Natasha Hernday to

    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Janux Therapeutics Promotes Co-Founder Tommy DiRaimondo, Ph.D. to Chief Scientific Officer

    Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the promotion of Dr. Tommy DiRaimondo to Chief Scientific Officer. "The appointment of Tommy to CSO is another important milestone for our company. Tommy was essential in our initial efforts to discover and engineer a tumor-activated technology for solid tumors and has since played a critical role in optimizing the applications for our TRACTr and TRACIr platforms while supporting our clinical

    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$JANX
Financials

Live finance-specific insights

See more
  • Janux Therapeutics Announces Positive Interim Clinical Data from Phase 1a Dose Escalation for PSMA-TRACTr JANX007 and an Update on Pipeline Programs

    Multiple patients treated with PSMA-TRACTr JANX007 have achieved meaningful PSA drops coupled with manageable safety and CRS PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008 have been generally well tolerated at levels above the projected maximum tolerable dose of the parental T cell engagers JANX007 preliminary data showed encouraging safety results consistent with on-tumor activity with no dose-limiting toxicities PK exposure demonstrated TRACTr activation with lack of TCE accumulation No treatment-emergent ADA titers observed Janux to host virtual investor event today at 4:00 PM Eastern Time Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutica

    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$JANX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more